AstraZeneca shares have had a terrible time of it in recent weeks. The Astra share price is down around 20% from recent highs, much of the losses recorded in the last couple of weeks.
Recently, results from the datopotamab deruxtecan lung cancer drug trial underwhelmed, with only marginally better outcomes for patients than existing therapies. Shares sank on the news.
However, a company the size of AstraZeneca has multiple drugs in their pipeline, and the lung cancer disappointment was followed quickly by positive news the FDA was considering their self-administered flu treatment.
AstraZenec...
